ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Li, Xi Ru ^a   Liu, Mei ^a   Zhang, Yan Jun ^a   Wang, Jian Dong ^a   Zheng, Yi Qiong ^a   Li, Jie ^a   Ma, Bing ^a   Song, Xin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

ER; Locally advanced breast cancer; Neoadjuvant chemotherapy; nm23 H1; PgR; Topo II

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

EID: 84655176743     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9693-y     Document Type: Article

References (46)

1. J Lee YH Im SH Lee 2008 Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer Cancer Chemother Pharmacol 61 569 577
2. B Fisher A Brown E Mamounas 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483 2493 (Pubitemid 27289876)
3. P Rastogi SJ Anderson HD Bear 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 778 785 (Pubitemid 351264391)
4. HM Kuerer LA Newman LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 (Pubitemid 29075229)
5. AU Buzdar NK Ibrahim D Francis 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685
6. V Guarneri K Broglio SW Kau 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 (Pubitemid 46638799)
7. JS Jeruss EA Mittendorf SL Tucker 2008 Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy J Clin Oncol 26 246 252
8. G von Minckwitz M Rezai S Loibl 2010 Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study J Clin Oncol 28 2015 2023
9. A Robidoux AU Buzdar E Quinaux 2010 A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer Clin Breast Cancer 10 81 86
10. V Ganansia-Leymarie P Bischoff JP Bergerat 2003 Signal transduction pathways of taxanes-induced apoptosis Curr Med Chem Anticancer Agents 3 291 306 (Pubitemid 36758303)
11. BK Sinha PM Politi 1990 Anthracyclines Cancer Chemother Biol Response Modif 11 45 57
12. DG Tiezzi JM Andrade A Ribeiro-Silva 2007 HER-2, p53, p21, hormonal receptors proteins expression as predictive factors of response, prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination BMC Cancer 7 36
13. AE Ring IE Smith S Ashley 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012 2017 (Pubitemid 40128767)
14. M Kaufmann G von Minckwitz R Smith 2003 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2600 2608 (Pubitemid 46606344)
15. M Colleoni G Viale D Zahrieh 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628 (Pubitemid 39346559)
16. L Harris H Fritsche R Mennel 2007 American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 (Pubitemid 350232263)
17. M Dowsett AK Dunbier 2008 Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer Clin Cancer Res 14 8019 8026
18. JL Hayward PP Carbone JC Heusen 1977 Assessment of response to therapy in advanced breast cancer Br J Cancer 35 292 298
19. A Goldhirsch JH Glick RD Gelber 2001 Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer J Clin Oncol 19 3817 3827 (Pubitemid 32880060)
20. A Di Leo D Larsimont D Gancberg 2001 HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12 1081 1089 (Pubitemid 32834488)
21. TW Jacobs AM Gown H Yaziji 1999 Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States food and drug Administrationapproved scoring system J Clin Oncol 17 1983 1987 (Pubitemid 29318825)
22. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 (Pubitemid 28363030)
23. JA van der Hage CJ van de Velde JP Julien 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902 J Clin Oncol 19 4224 4237
24. M Tewari A Krishnamurthy HS Shukla 2008 Predictive markers of response to neoadjuvant chemotherapy in breast cancer Surg Oncol 17 301 311
25. DS Subramaniam C Isaacs 2005 Utilizing prognostic and predictive factors in breast cancer Curr Treat Options Oncol 6 147 159 (Pubitemid 40392701)
26. L Wang Z Jiang M Sui 2009 The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study BMC Cancer 9 226
27. M Colleoni G Viale D Zahrieh 2008 Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann Oncol 19 465 472 (Pubitemid 351325666)
28. G von Minckwitz HP Sinn G Raab 2008 Clinical response after two cycles compared to HER2, Ki-67, p53, bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Breast Cancer Res 10 R30
29. CR Berney RJ Fisher J Yang 1999 Protein markers in colorectal cancer: predictors of liver metastasis Ann Surg 230 179 184 (Pubitemid 30191883)
30. N Iizuka K Hirose T Noma 1999 The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma Br J Cancer 81 469 475 (Pubitemid 29458801)
31. G Scambia G Ferrandina M Marone 1996 nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters J Clin Oncol 14 334 342 (Pubitemid 26053263)
32. N Iizuka K Miyamoto A Tangoku 2000 Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase Br J Cancer 83 1209 1215
33. F Penault-Llorca C Abrial I Raoelfils 2008 Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy Oncologist 13 1235 1245
34. P Collecchi E Baldini P Giannessi 1998 Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers Eur J Cancer 34 1701 1704 (Pubitemid 28474222)
35. J Chang M Ormerod TJ Powles 2000 Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma Cancer 89 2145 2152
36. A Vincent-Salomon A Rousseau M Jouve 2004 Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy Eur J Cancer 40 1502 1508 (Pubitemid 38757737)
37. RJ Burcombe A Makris PI Richman 2005 Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 147 155 (Pubitemid 40188448)
38. M Colleoni E Orvieto F Nolé 1999 Prediction of response to primary chemotherapy for operable breast cancer Eur J Cancer 35 4 574 579 (Pubitemid 29192965)
39. IF Faneyte JG Schrama JL Peterse 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412 (Pubitemid 36308152)
40. A Gennari MP Sormani P Pronzato 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 (Pubitemid 351767337)
41. JS Coon E Marcus S Gupta-Burt 2002 Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 1061 1067 (Pubitemid 35177356)
42. G [tmp] MacGrogan P Rudolph I Mascarel Id 2003 DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer Br J Cancer 89 666 671 (Pubitemid 37076170)
43. M Tanner J Isola T Wiklund 2006 Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 2428 2436 (Pubitemid 46630618)
44. L Orlando B Del Curto S Gandini 2008 Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer Breast 17 506 511
45. T Petit M Wilt M Velten 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 205 211 (Pubitemid 38077022)
46. A Rody T Karn R Gätje 2007 Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response Breast 16 86 93 (Pubitemid 46172862)